Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study

著者: Claire Harrison, Nicolaas Schaap, Alessandro M. Vannucchi, Jean‐Jacques Kiladjian, Ramón V. Tiu, Pierre Zachée, Éric Jourdan, Elliott F. Winton, Richard T. Silver, Harry C. Schouten, Francesco Passamonti, Sonja Zweegman, Moshe Talpaz, Joanne Lager, Zhenming Shun, Ruben A. Mesa - The Lancet 2017 被引用: 330